Brain Involvement in Neuromyelitis Optica Spectrum Disorders

被引:85
|
作者
Chan, Koon Ho [1 ,2 ,3 ]
Tse, C. T. [1 ]
Chung, C. P. [1 ]
Lee, Raymand L. C. [1 ]
Kwan, J. S. C. [1 ,2 ]
Ho, P. W. L. [1 ,3 ]
Ho, J. W. M. [1 ]
机构
[1] Univ Hong Kong, Dept Med, Queen Mary Hosp, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Neuroimmunol & Neuroinflammat Res Lab, Queen Mary Hosp, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Res Ctr Heart Brain Hormone & Hlth Aging, Queen Mary Hosp, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China
关键词
INFLAMMATORY DEMYELINATING DISORDERS; RESONANCE-IMAGING ABNORMALITIES; ANTI-AQUAPORIN-4; ANTIBODY; MULTIPLE-SCLEROSIS; DIAGNOSTIC-CRITERIA; CLINICAL-COURSE; WATER CHANNEL; IGG; NMO; RITUXIMAB;
D O I
10.1001/archneurol.2011.249
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neuromyelitis optica spectrum disorders (NMOSDs) are severe inflammatory demyelinating disorders of the central nervous system. Brain involvement is increasingly recognized. Objective: To study brain involvement in NMOSDs among Hong Kong Chinese patients. Design: Retrospective study of patients with NMOSDs. Setting: Tertiary medical center in Hong Kong. Patients: Thirty-four Hong Kong Chinese patients with NMOSDs of 2 years or longer were recruited. Interventions: Brain and spinal cord magnetic resonance imaging was performed during NMOSD attacks and was repeated yearly for the first 3 years. Main Outcome Measures: We evaluated clinical features of NMOSDs associated with brain involvement and brain lesions on magnetic resonance imaging. Results: Among 34 patients with NMOSDs of 2 years or longer, 20 (59%) had brain involvement. The mean age at onset among these 20 patients was 45.6 years (age range, 19-67 years); 18 were women. Eleven patients (32% of all the patients with NMOSDs) had clinical manifestation of brain involvement, 19 patients (56%) had brain abnormalities on magnetic resonance imaging consistent with inflammatory demyelination, and 2 patients (6%) fulfilled criteria for multiple sclerosis. Clinical manifestation of brain involvement included the following: trigeminal neuralgia; vomiting, vertigo, ataxia, dysphagia, and tetraparesis from lesions around the third and fourth ventricles and aqueduct; homonymous hemianopia, aphasia, hemiparesis, and cognitive impairment from extensive hemispheric white matter lesions; and ataxia, diplopia, hiccups, facial sensory loss, internuclear ophthalmoplegia, hemisensory loss, and hemiparesis from other lesions in the midbrain, pons, cerebellar peduncles, and medulla. Eight patients (24%) developed brainstem encephalitis clinically, and brainstem encephalitis was the initial clinical manifestation in 6 patients (18%). Brain abnormalities on magnetic resonance imaging were detected in brainstem in 15 patients (44%), hemispheric periventricular white matter in 7 patients (21%), deep white matter in 7 patients (21%), corpus callosum in 4 patients (12%), subcortical white matter in 3 patients (9%), thalamus in 2 patients (6%), hypothalamus in 1 patient (3%), basal ganglia in 1 patient (3%), internal capsule in 1 patient (3%), periaqueductal gray matter in 1 patient (3%), and around the third and fourth ventricles in 1 patient (3%); large confluent lesions were detected in 2 patients (6%). Conclusion: Brain involvement manifesting clinically as brainstem encephalitis is common among Hong Kong Chinese patients with NMOSDs.
引用
收藏
页码:1432 / 1439
页数:8
相关论文
共 50 条
  • [41] Neuromyelitis Optica Spectrum Disorders (NMOSD)
    Glisson, Christopher C.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2022, 24 (06) : 241 - 251
  • [42] Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Lucchinetti, Claudia F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (07): : 631 - 639
  • [43] Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist
    Cruz, Roberto A.
    Chaudhary, Sana
    Guevara, Myriam
    Meltzer, Ethan
    CURRENT RHEUMATOLOGY REPORTS, 2021, 23 (06)
  • [44] Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
    Kleiter, Ingo
    Gold, Ralf
    NEUROTHERAPEUTICS, 2016, 13 (01) : 70 - 83
  • [45] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [46] Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders
    Valencia-Sanchez, Cristina
    Wingerchuk, Dean M.
    BIODRUGS, 2021, 35 (01) : 7 - 17
  • [47] Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management
    Shosha, Eslam
    Pittock, Sean J.
    Flanagan, Eoin
    Weinshenker, Brian G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1808 - 1817
  • [48] Pruritus in neuromyelitis optica spectrum disorders and multiple sclerosis
    He, Mianwang
    Wu, Lei
    Huang, Dehui
    Yau, Vicky
    Yu, Shengyuan
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 79 : 108 - 112
  • [49] Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?
    Cai, Haobing
    Zhou, Ran
    Jiang, Fei
    Zeng, Qiuming
    Yang, Huan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [50] Magnetic resonance imaging in neuromyelitis optica spectrum disorders
    Vaneckova, M.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 : S20 - S30